Abstract: Systems and methods for tracking data lineage and record lifecycle using a distributed ledger are disclosed. In one embodiment, a method for tracking record lifecycle events may include: (1) creating, by a record lifecycle tool, a recordable artifact for a record lifecycle event in a record lifecycle, the recordable artifact comprising data for the record lifecycle event; (2) generating, by the record lifecycle tool, a hash of the data; (3) creating, by the record lifecycle tool, record lifecycle event metadata for the recordable artifact; (4) signing, by the record lifecycle tool, the record lifecycle event metadata; (5) writing the record lifecycle event metadata to supply chain metadata storage at a storage location, wherein the supply chain metadata storage may be cryptographically verifiable and immutable; and (6) writing the hash and an identifier for the storage location in the supply chain metadata store to a present state database.

Abstract: A method for facilitating identification of secrets in source code by using machine learning is provided. The method includes retrieving a plurality of files from a repository, each of the plurality of files including a source code file; parsing the source code file to identify a training feature; associating a predetermined label with the training feature, the predetermined label corresponding to a secret label and a non-secret label; training a model by using the training feature and the corresponding predetermined label; receiving, via a graphical user interface, a test file, the test file including a set of source codes; parsing the set of source codes to identify a feature; and determining, by using the model, a first characteristic of the feature.

Abstract: A method for facilitating identification of secrets in source code by using machine learning is provided. The method includes retrieving a plurality of files from a repository, each of the plurality of files including a source code file; parsing the source code file to identify a training feature; associating a predetermined label with the training feature, the predetermined label corresponding to a secret label and a non-secret label; training a model by using the training feature and the corresponding predetermined label; receiving, via a graphical user interface, a test file, the test file including a set of source codes; parsing the set of source codes to identify a feature; and determining, by using the model, a first characteristic of the feature.

Abstract: The present invention relates to a non-aqueous composition that comprises a permeation enhancer such as a terpene, for delivering an active ingredient transdermally. The composition comprises at least on one active ingredient, a terpene, and a solvent, such as a non-hydroxyl containing solvent, non-heterocyclic ester solvent and/or a tripropylene glycol alkyl ether. The composition can be used to deliver a range of actives, such as anthelmintics. The present invention provides a platform composition and can be used to deliver a wide variety of active ingredients and combinations thereof transdermally to mammals.

Abstract: Systems and methods for distributed ledger-based software supply chain management are disclosed. According to one embodiment, in an information processing apparatus comprising at least one computer processor, a method for distributed ledger-based software supply chain management may include: (1) receiving, from a software tool, a metadata artifact for a software development lifecycle event; (2) writing the metadata artifact to a metadata store; and (3) updating a present state database with values for metadata keys referencing the metadata artifact in the metadata store.

Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.

Abstract: Systems and methods for distributed ledger-based software supply chain management are disclosed. According to one embodiment, in an information processing apparatus comprising at least one computer processor, a method for distributed ledger-based software supply chain management may include: (1) receiving, from a software tool, a metadata artifact for a software development lifecycle event; (2) writing the metadata artifact to a metadata store; and (3) updating a present state database with values for metadata keys referencing the metadata artifact in the metadata store.

Abstract: The present inventors have harnessed the targeting of nanoparticles to tumor sites, combined with the tumor site specific elevated MMP-14 activity within one conjugate to simultaneously deliver a vascular disrupting agent (VDA) and a MRI contrast agent to a tumor site. The MMP activatable conjugate of the present invention provides both therapeutic and diagnostic functions—and is referred to as a “theranostic”. The theranostic conjugate of the present invention achieves the benefits of tumor site specificity, VDA delivery and MRI contrast agent delivery in a single theranostic conjugate. Consequently, the present invention provides a cancer “theranostic” which improves therapeutic efficacy while simultaneously reducing dose-limiting systemic toxicities and provides a tool for rapidly and non-invasively identifying tumor location, monitoring drug delivery and pharmacodynamics.

Abstract: The present invention harnesses the differential expression of membrane-type matrix metalloproteinases (MT-MMPs) between human solid tumours and normal tissues to provide a systemically inactive prodrug which is selectively activated at the tumour micro-environment. The present invention provides a prodrug which is a conjugate of a taxane and a selective MT-MMP cleavable delivery vehicle.

Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.

Abstract: The present inventors have harnessed the targeting of nanoparticles to tumour sites, combined with the tumour site specific elevated MMP-14 activity within one conjugate to simultaneously deliver a vascular disrupting agent (VDA) and a MRI contrast agent to a tumour site. The MMP activatable conjugate of the present invention provides both therapeutic and diagnostic functions—and is referred to as a “theranostic”. The theranostic conjugate of the present invention achieves the benefits of tumour site specificity, VDA delivery and MRI contrast agent delivery in a single theranostic conjugate. Consequently, the present invention provides a cancer “theranostic” which improves therapeutic efficacy whilst simultaneously reducing dose-limiting systemic toxicities and provides a tool for rapidly and non-invasively identifying tumour location, monitoring drug delivery and pharmacodynamics.

Abstract: The present invention relates to a non-aqueous composition that comprises a permeation enhancer such as a terpene, for delivering an active ingredient transdermally. The composition comprises at least on one active ingredient, a terpene, and a solvent, such as a non-hydroxyl containing solvent, non-heterocyclic ester solvent and/or a tripropylene glycol alkyl ether. The composition can be used to deliver a range of actives, such as anthelmintics. The present invention provides a platform composition and can be used to deliver a wide variety of active ingredients and combinations thereof transdermally to mammals.

Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a matrix metalloproteinase (MMP) proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.

Abstract: The invention relates to compounds which are useful in the delivery of a wide variety of therapeutically useful molecules. In particular, the invention relates to compounds which are able to act as carriers for therapeutically useful molecules, and to pharmaceutical agents comprising these carriers. The compounds of the invention comprise a mono- or oligosaccharide, a lipidic moiety, and optionally a linker and/or a spacer. The pharmaceutical agents of the invention are particularly useful for oral administration.

Abstract: The invention relates to compounds which are useful in the delivery of a wide variety of therapeutically useful molecules. In particular, the invention relates to compounds which are able to act as carriers for therapeutically useful molecules, and to pharmaceutical agents comprising these carriers. The compounds of the invention comprise a mono- or oligosaccharide, a lipidic moiety, and optionally a linker and/or a spacer. The pharmaceutical agents of the invention are particularly useful for oral administration.

Abstract: A method for drying, curing and mining bentonite clay in a clay pit wherein that overburden of non-clay material which may exist is removed and the surface of the bentonite ore body is tilled to loosen or break up a tier of the bentonite to expose it to the natural drying and curing effects of the atmosphere, the dried and cured tier of bentonite is removed thus exposing another tier of uncured bentonite, which is again tilled for drying and curing, and the process is repeated until the bentonite ore body is exhausted.